.svg?iar=0&updated=20230109065058&hash=B8F025B8AA9A24E727DBB30EAED272C8){kind=logo}
2006 patients with HF within 2-9 days of MI
Study Treatment
Ramipril 5 mg/day vs Placebo
Study Period
4 weeks
Results
- Progression to severe resistant heart failure reduced significantly by 23% vs placebo
- Ramipril significantly reduced the risk of rehospitalization by 26% vs placebo
- Significant reduction in risk of sudden death by 30% vs placebo
Conclusion
Ramipril significantly reduces mortality & progression to resistant HF in patients with HF post MI
Eur Heart J 1997;18:41-51
